Conversely, RFWD2 was regarded as a tumor promoter in human hepatocellular carcinoma, breast cancer, ovarian adenocarcinoma and acute myeloid leukemia (Dornan et al., 2004a; Lee et al., 2010; Yoshida et al., 2013). This evidence concerns the gene COP1 and neoplasm.